HUMAN MESENCHYMAL STEM CELL-CONDITIONED MEDIUM AND HUMAN MESENCHYMAL STEM CELLS FOR USE IN TREATMENT OF CHRONIC HEART-LUNG AND VASCULAR DISEASES, IN PARTICULAR, OF PULMONARY ARTERIAL HYPERTENSION (PAH)
The present invention relates to the field of medical treatment of chronic disease with stem-cell derived products, in particular, human mesenchymal stem cell-derived treatment of chronic heart-lung and vascular diseases. The inventors provide human mesenchymal stem cell-conditioned medium, such as human umbilical cord mesenchymal stem cell-conditioned medium (HUMSC-CM) for use in treatment of chronic heart-lung and vascular diseases, in particular, pulmonary hypertension (PH, groups 1-5), such as pulmonary arterial hypertension (PAH; group 1 PH according to World Symposium on Pulmonary Hypertension 2018 ). The invention also provides a method of treating chronic heart-lung-vascular diseases by means of administering such conditioned medium intravascularily. Optionally, the treatment may additionally comprise administering human umbilical cord mesenchymal stem cells to the patient..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 07. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HANSMANN GEORG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-07, Last update posted on www.tib.eu: 2023-12-27, Last updated: 2024-01-05 |
|---|
| Patentnummer: |
WO2023232914 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018866107 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018866107 | ||
| 003 | DE-627 | ||
| 005 | 20240105084945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018866107 | ||
| 035 | |a (EPA)WO2023232914 | ||
| 035 | |a (EPA)82458475 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HANSMANN GEORG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HUMAN MESENCHYMAL STEM CELL-CONDITIONED MEDIUM AND HUMAN MESENCHYMAL STEM CELLS FOR USE IN TREATMENT OF CHRONIC HEART-LUNG AND VASCULAR DISEASES, IN PARTICULAR, OF PULMONARY ARTERIAL HYPERTENSION (PAH) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-07, Last update posted on www.tib.eu: 2023-12-27, Last updated: 2024-01-05 | ||
| 520 | |a The present invention relates to the field of medical treatment of chronic disease with stem-cell derived products, in particular, human mesenchymal stem cell-derived treatment of chronic heart-lung and vascular diseases. The inventors provide human mesenchymal stem cell-conditioned medium, such as human umbilical cord mesenchymal stem cell-conditioned medium (HUMSC-CM) for use in treatment of chronic heart-lung and vascular diseases, in particular, pulmonary hypertension (PH, groups 1-5), such as pulmonary arterial hypertension (PAH; group 1 PH according to World Symposium on Pulmonary Hypertension 2018 ). The invention also provides a method of treating chronic heart-lung-vascular diseases by means of administering such conditioned medium intravascularily. Optionally, the treatment may additionally comprise administering human umbilical cord mesenchymal stem cells to the patient. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HASS RALF |4 aut | |
| 700 | 0 | |a GIERA MARTIN |4 aut | |
| 700 | 0 | |a RALSER MARKUS |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 07. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:07 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/82458475/publication/WO2023232914A1?q=WO2023232914 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 07 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 07 |c 12 | ||